LY-4066434

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameLY-4066434
Drug Alias NameLY-4066434
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLoxo Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesLilly Suzhou Pharmaceutical Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A